SENSIPAR Drug Patent Profile

When do Sensipar patents expire, and what generic alternatives are available?

Sensipar is a drug marketed by Amgen and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has eighty-one patent family members in twenty-nine countries.

The generic ingredient in SENSIPAR is cinacalcet hydrochloride. There are twenty-four drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the cinacalcet hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Sensipar

A generic version of SENSIPAR was approved as cinacalcet hydrochloride by AUROBINDO PHARMA LTD on March 8^th, 2018.

Summary for SENSIPAR

International Patents:	81
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	75
Clinical Trials:	17
Patent Applications:	391
Drug Prices:	Drug price information for SENSIPAR
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for SENSIPAR
What excipients (inactive ingredients) are in SENSIPAR?	SENSIPAR excipients list
DailyMed Link:	SENSIPAR at DailyMed

See drug prices for SENSIPAR

Recent Clinical Trials for SENSIPAR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
VA Office of Research and Development	Phase 4
University of California, San Francisco	Phase 4
Aalborg University	Phase 3

See all SENSIPAR clinical trials

Pharmacology for SENSIPAR

Drug Class	Calcium-sensing Receptor Agonist
Mechanism of Action	Increased Calcium-sensing Receptor Sensitivity

Paragraph IV (Patent) Challenges for SENSIPAR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SENSIPAR	Tablets	cinacalcet hydrochloride	30 mg, 60 mg and 90 mg	021688	1	2008-03-10

US Patents and Regulatory Information for SENSIPAR

SENSIPAR is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Amgen	SENSIPAR	cinacalcet hydrochloride	TABLET;ORAL	021688-001	Mar 8, 2004		DISCN	Yes	No	7,829,595		Y
Amgen	SENSIPAR	cinacalcet hydrochloride	TABLET;ORAL	021688-002	Mar 8, 2004		DISCN	Yes	No	9,375,405		Y
Amgen	SENSIPAR	cinacalcet hydrochloride	TABLET;ORAL	021688-001	Mar 8, 2004		DISCN	Yes	No	9,375,405		Y
Amgen	SENSIPAR	cinacalcet hydrochloride	TABLET;ORAL	021688-002	Mar 8, 2004		DISCN	Yes	No	7,829,595		Y
Amgen	SENSIPAR	cinacalcet hydrochloride	TABLET;ORAL	021688-003	Mar 8, 2004		DISCN	Yes	No	9,375,405		Y
Amgen	SENSIPAR	cinacalcet hydrochloride	TABLET;ORAL	021688-003	Mar 8, 2004		DISCN	Yes	No	7,829,595		Y

Expired US Patents for SENSIPAR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Amgen	SENSIPAR	cinacalcet hydrochloride	TABLET;ORAL	021688-002	Mar 8, 2004	6,313,146
Amgen	SENSIPAR	cinacalcet hydrochloride	TABLET;ORAL	021688-001	Mar 8, 2004	6,011,068
Amgen	SENSIPAR	cinacalcet hydrochloride	TABLET;ORAL	021688-001	Mar 8, 2004	6,211,244
Amgen	SENSIPAR	cinacalcet hydrochloride	TABLET;ORAL	021688-003	Mar 8, 2004	6,011,068
Amgen	SENSIPAR	cinacalcet hydrochloride	TABLET;ORAL	021688-002	Mar 8, 2004	6,211,244
Amgen	SENSIPAR	cinacalcet hydrochloride	TABLET;ORAL	021688-003	Mar 8, 2004	6,313,146
Amgen	SENSIPAR	cinacalcet hydrochloride	TABLET;ORAL	021688-002	Mar 8, 2004	6,031,003

International Patents for SENSIPAR

See the table below for patents covering SENSIPAR around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	264292
Austria	287390
Austria	312347
Austria	313321
Austria	359259
Australia	1014100
Australia	2588992

Supplementary Protection Certificates for SENSIPAR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1203761	CA 2005 00027	Denmark
1203761	300199	Netherlands
1203761	SPC/GB05/031	United Kingdom		PRODUCT NAME: CINACALCET OR A PHARMACEUTICALLY ACCEPTABLE SALT OR COMPLEX THEREOF; REGISTERED: UK EU/1/04/292/001 20041022; UK EU/1/04/292/002 20041022; UK EU/1/04/292/003 20041022; UK EU/1/04/292/004 20041022; UK EU/1/04/292/005 20041022; UK EU/1/04/292/006 20041022; UK EU/1/04/292/007 20041022; UK EU/1/04/292/008 20041022; UK EU/1/04/292/009 20041022; UK EU/1/04/292/010 20041022; UK EU/1/04/292/011 20041022; UK EU/1/04/292/012 20041022; UK EU/1/04/293/001 20041022; UK EU/1/04/293/002 20041022; UK EU/1/04/293/003 20041022; UK EU/1/04/293/004 20041022; UK EU/1/04/293/005 20041022; UK EU/1/04/293/006 20041022; UK EU/1/04/293/007 20041022; UK EU/1/04/293/008 20041022; UK EU/1/04/293/009 200410
1203761	SPC020/2005	Ireland		SPC020/2005: 20060407, EXPIRES: 20191021
1203761	91182	Luxembourg		91182, EXPIRES: 20191022
1203761	05C0029	France		PRODUCT NAME: CINACALCET; REGISTRATION NO/DATE: EU/01/04/292/001-012 20041022
1203761	C01203761/01	Switzerland		PRODUCT NAME: CINACALCETUM; REGISTRATION NUMBER/DATE: SWISSMEDIC 56965 27.10.2004

SENSIPAR (cinacalcet) Market Dynamics and Financial Trajectory: Exclusivity, Competition, Revenue Outlook, and Key Risk Factors

Last updated: July 1, 2026

Executive summary: Sensipar (cinacalcet), a calcimimetic for secondary hyperparathyroidism (sHPT) in CKD and for hypercalcemia in parathyroid carcinoma and primary hyperparathyroidism (pHPT), is an established market with mature generic exposure in most major geographies. The near-to-medium-term financial trajectory is driven primarily by: (1) generic penetration speed and share capture post-launch, (2) payer formulary placement and rebates versus newer competitors, (3) maintenance dosing tolerance and persistence, and (4) sensitivity to ESRD and dialysis volume trends. Brand revenue is already structurally compressed versus launch-era peaks, with remaining value tied to brand-managed contracts, channel rebates, and residual IP-protected line extensions (limited).

What is Sensipar and what revenue base does it have today?
Sensipar is the branded form of cinacalcet, marketed by Amgen in the US. The active ingredient is used in:

• Secondary hyperparathyroidism (sHPT) in patients with chronic kidney disease on dialysis (and in some labeled CKD non-dialysis populations depending on country/label history).
• Hypercalcemia in parathyroid carcinoma.
• Hypercalcemia in primary hyperparathyroidism where surgery is not appropriate or is contraindicated.

Because cinacalcet is no longer protected by meaningful primary-use exclusivity in the US and most large markets, the brand’s financial trajectory is governed by generic pricing, rebate structures, and the speed at which new entrants gain preferred status.

---

What market dynamics determine Sensipar (cinacalcet) brand share versus generics?

Answer: Brand share is driven by rebate competitiveness, payer formulary dynamics, and channel switching economics after generic entry. For established oral oncology-adjacent supportive and nephrology chronic-use drugs, payers typically move quickly once multiple generics are available and ASP erosion accelerates.

Key demand-side drivers

1. Dialysis and CKD prevalence trends

   • Sensipar’s sHPT indication tracks ESRD incidence and dialysis patient counts.
   • Any shift in dialysis growth rate, treatment intensity, and patient survival changes the addressable patient pool.

2. Mineral bone disorder (MBD) practice patterns

   • Use of vitamin D analogs, phosphate binders, and calcimimetics affects dosing uptake.
   • Clinician dosing behavior is highly sensitive to safety monitoring needs (notably calcium and PTH).

3. Adherence and persistence

   • Cinacalcet is chronic. Persistence is strongly affected by tolerability and laboratory monitoring cadence.
   • Generic substitution does not always reduce adherence if the dosing schedule is maintained, but switching can temporarily disrupt persistence if titration protocols differ.

Key supply-side drivers

1. Generic entry multiplicity

   • Each additional ANDA/authorized generic entrant typically compresses net price further.
   • By late lifecycle, the “market-clearing price” is set by the lowest-cost preferred vendor among contracted suppliers.

2. Formulary tiering and rebate leverage

   • Long-term contracts can delay full replacement, but once payers build “must-have” economics around generics, brand leverage drops.

3. Product access in institutional channels

   • Renal clinics and large dialysis organizations often standardize formularies across sites, speeding utilization shifts after competitive availability.

---

When did Sensipar (cinacalcet) lose market exclusivity, and what does that imply for revenue?

Answer: Sensipar’s effective brand exclusivity has long ended in the US and major ex-US markets; revenue is now predominantly a function of contract-driven brand retention and residual differentiation, not legal exclusivity.

US exclusivity timeline dynamics

• The brand’s IP moat for cinacalcet has been overtaken by generic competition over time.
• Post-exclusivity, brand revenue typically transitions to a “share maintenance” strategy rather than growth: lower net price ceilings, higher rebate pressure, and declining market share versus multi-source generics.

Implication for the financial trajectory

• Structural downtrend: net sales trend is dominated by ASP erosion and share loss.
• Stability risk: even when patient numbers grow, price decline can outweigh volume gains.
• Volatility risk: contract expirations can cause step-change net sales drops.

---

What patents protect Sensipar (cinacalcet) today, and how do they affect competition?

Answer: Sensipar’s current competitive landscape is driven mainly by generic availability rather than active brand exclusivity. Any remaining patent tail tends to be limited to specific formulations, methods, or secondary filings, which only delay narrowly defined entry rather than block full competition.

Patent estate typical pattern for mature brands (relevant to cinacalcet)

• Primary drug substance patents expired years earlier.
• Later filings (if any) often cover:
  • specific dosage/formulations,
  • dosing regimens or monitoring methods, or
  • manufacturing-related claims.

Practical effect

• Generic entrants usually launch with “skinny labels” where allowed and/or design around remaining protected aspects, especially when the core therapeutic value is not tied to those narrow claims.

---

What is the Orange Book status of Sensipar (cinacalcet), and how many ANDAs/generics exist?

Answer: The Orange Book for cinacalcet (Sensipar) lists multiple FDA-approved generic versions for each dosage form, reflecting extensive multi-source availability. In practice, the Orange Book status indicates that the branded product does not retain market-wide exclusivity in the US.

What to expect from Orange Book listings

• Generic entries typically include “paragraph III” or “paragraph IV” certifications depending on patent status and whether patents were asserted at the time.
• Current brand viability depends on residual protected listings only if they prevent immediate generic substitution for specific strengths/forms.

---

How strong is the patent estate for Sensipar versus other calcimimetics and nephrology mineral bone disorder drugs?

Answer: In the calcimimetic class and broader MBD space, the competitive threat is genericization of cinacalcet rather than dominant new branded calcimimetic IP. The main differentiation in the market comes from price and contracts, not patent-driven product superiority.

Competitive set in CKD-MBD

• Calcimimetics (cinacalcet and derivatives where applicable)
• Vitamin D analogs and calcitriol-like therapies
• Phosphate binders (which shift PTH control strategies)

Because cinacalcet is the anchor oral calcimimetic for many patients, therapeutic switching from cinacalcet is possible but constrained by efficacy and tolerability.

---

What generic entry risks exist for Sensipar, and how do Paragraph IV challenges shape market share?

Answer: Generic entry risk is already realized in most mature markets. Remaining risk is mainly contract-driven: additional entrants or authorized generics can deepen price erosion and accelerate share loss among commercial patients and institutions.

Paragraph IV and litigation impact (how it typically plays out)

• Paragraph IV challenges create temporary “brand-held share” when litigation delays launch.
• Once litigation concludes or patents expire, market share typically shifts quickly because payers have established substitution pathways.

---

How does Sensipar compare with other CKD-MBD therapies on market economics?

Answer: Sensipar’s economic profile is shaped by multi-source generic competition and a payer view of “therapeutic class interchangeability” around PTH control. In contrast, therapies with fewer generics or stronger clinical differentiation can hold higher net pricing for longer.

Key comparison axes

• Net price ceiling: brands face the lowest price floor once multiple generics are available.
• Formulary positioning: payers prefer regimens that minimize total MBD management costs.
• Monitoring burden: lab monitoring requirements can influence internal pathway adoption, but are similar across cinacalcet-based dosing strategies.

---

What FDA regulatory status applies to Sensipar, and how does it influence market access?

Answer: Sensipar remains FDA-approved for its labeled indications. The regulatory status affects labeling consistency and substitution behavior more than it affects brand revenues directly, since generic versions hold approval for the same active ingredient and strength/dosage forms.

Market access mechanism

• Substitution under pharmacy benefit plans uses approved equivalency rather than brand-only regulatory differentiation.
• Safety reporting and label requirements can drive monitoring protocols, but do not generally protect brand economics once generics are available.

---

How do manufacturing and supply constraints affect Sensipar pricing and sales?

Answer: In mature multi-source markets, supply constraints usually affect short-term pricing and may widen brand or specific generic contracts temporarily. However, sustained financial impact is less likely unless there are concentrated supply disruptions across key vendors.

Where disruption shows up

• Shortages can temporarily lift net pricing for remaining suppliers.
• Contracting behavior among dialysis organizations can create localized volatility if contracted suppliers become unavailable.

---

Commercial trajectory: where is Sensipar revenue most exposed?

Answer: Revenue exposure concentrates in: (1) commercial and Medicaid plans with aggressive generic step therapy, (2) institutional tender markets for dialysis-related MBD medications, and (3) geography where generic penetration is incomplete.

Geographic exposure pattern

• US: brand is maximally pressured by multi-source generics and rebate-driven substitution.
• Europe and other developed markets: generally higher generic penetration over time, but the pace differs by country.
• Emerging markets: may show longer persistence of branded availability if reimbursement and tender structures lag generic adoption.

---

Financial outlook: what trajectory should be expected for Sensipar (cinacalcet) over the next 3–5 years?

Answer: The baseline trajectory is continued net sales erosion from price pressure offset partly by patient volume stability. Upside is limited to incremental share retention via payer contracting and any localized supply dynamics; downside is driven by contract resets, increased generic competition intensity, and therapy mix shifts within CKD-MBD.

Bull-case drivers (practical)

• Stronger than expected persistence in patients who already titrate to cinacalcet.
• Contracted brand retention where payers maintain brand-only ordering through preferred pharmacy networks.
• Temporary pricing uplift from supplier constraints or rebate renegotiation.

Bear-case drivers (practical)

• Faster institutional tender switching when additional generic suppliers enter.
• Rebate pressure increases at renewal, pushing net ASP down faster than patient volumes rise.
• Therapy mix moves toward alternate regimens where phosphate binder and vitamin D strategies reduce cinacalcet reliance at the margin.

---

Key takeaways

• Sensipar’s financial trajectory is dominated by generic competition economics rather than live exclusivity.
• Market share and net sales are most sensitive to payer rebates, dialysis institutional formularies, and contract renewal timing.
• Demand is tied to CKD and dialysis prevalence, but price erosion typically outweighs volume growth.
• The main “growth” lever is not IP but commercial contracting and continuity of dosing in established patients.

---

FAQs

1) How does generic substitution change Sensipar net pricing versus gross unit sales?
Generic substitution typically reduces net pricing sharply due to rebate re-optimization and ASP compression, while unit volumes may remain stable or rise modestly because dosing continues.

2) Is Sensipar more exposed to commercial payer switches or to institutional dialysis formularies?
Institutional dialysis formularies often switch faster because tenders and standardized MBD pathways accelerate vendor consolidation.

3) What safety monitoring requirements drive clinician persistence with cinacalcet?
Cinacalcet therapy requires periodic calcium and PTH monitoring and dose titration, which supports persistence once a patient is stable but can increase short-term discontinuation risk during early titration.

4) What competitive pressure comes from therapies beyond calcimimetics in CKD-MBD?
Phosphate binders and vitamin D analog strategies influence PTH control targets and can reduce reliance on calcimimetics at the margin for some patients.

5) Does supply availability materially affect Sensipar revenue in the long run?
Supply constraints can cause short-term pricing variability, but long-run revenue is dominated by multi-source pricing and contract structures.

---

References (APA)

1. FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
2. FDA. (n.d.). Drug Trials Snapshots: Cinacalcet (Sensipar). U.S. Food and Drug Administration.
3. Drugs@FDA. (n.d.). Cinacalcet (Sensipar). U.S. Food and Drug Administration.
4. IMS/IQVIA and other market datasets. (n.d.). CKD-MBD market and brand/generic share reports (subscription databases).